Chang J, Hong L, Liu Y. Cancer Manag Res. 2020;12:2641–2651.
The authors have advised that there is an error in Figure 2E on page 2646. The correct figure is shown below.
The authors apologize for this error.
. 2020 May 12;12:3331–3332. doi: 10.2147/CMAR.S260280
Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer [Corrigendum]
Received 2020 Apr 28; Accepted 2020 Apr 28; Collection date 2020.
© 2020 Chang et al.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
PMCID: PMC7234805 PMID: 32494196
This corrects the article "Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer" on page 2641.